Notice: Trading of Pulmatrix halted at 10:42 AM EST due to "LULD pause". Pulmatrix (PULM) Competitors $4.70 +1.14 (+32.02%) (As of 04:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PULM vs. ACXP, ALTS, EYEN, INKT, PMN, PLUR, RNXT, TPST, ICCC, and ESLAShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Acurx Pharmaceuticals (ACXP), Janone (ALTS), Eyenovia (EYEN), MiNK Therapeutics (INKT), ProMIS Neurosciences (PMN), Pluri (PLUR), RenovoRx (RNXT), Tempest Therapeutics (TPST), ImmuCell (ICCC), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Acurx Pharmaceuticals Janone Eyenovia MiNK Therapeutics ProMIS Neurosciences Pluri RenovoRx Tempest Therapeutics ImmuCell Estrella Immunopharma Pulmatrix (NASDAQ:PULM) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the MarketBeat Community prefer PULM or ACXP? Pulmatrix received 183 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 92.86% of users gave Acurx Pharmaceuticals an outperform vote while only 49.12% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19649.12% Underperform Votes20350.88% Acurx PharmaceuticalsOutperform Votes1392.86% Underperform Votes17.14% Do analysts prefer PULM or ACXP? Acurx Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 577.97%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PULM or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pulmatrix's return on equity of -45.97% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Acurx Pharmaceuticals N/A -349.90%-210.75% Do institutionals & insiders have more ownership in PULM or ACXP? 11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 3.6% of Pulmatrix shares are owned by insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, PULM or ACXP? Pulmatrix has higher revenue and earnings than Acurx Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$11.39M1.78-$14.12M-$2.64-2.10Acurx PharmaceuticalsN/AN/A-$14.58M-$1.09-1.62 Which has more volatility & risk, PULM or ACXP? Pulmatrix has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.73, meaning that its stock price is 273% less volatile than the S&P 500. Does the media prefer PULM or ACXP? In the previous week, Pulmatrix and Pulmatrix both had 9 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.21 beat Pulmatrix's score of 0.03 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAcurx Pharmaceuticals beats Pulmatrix on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.27M$7.11B$5.33B$8.91BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-2.1011.25135.4417.46Price / Sales1.78393.051,266.8895.47Price / CashN/A49.2238.8936.42Price / Book1.869.126.315.92Net Income-$14.12M$153.75M$118.33M$224.86M7 Day Performance166.83%-1.20%-1.43%-0.38%1 Month Performance163.03%8.48%3.12%4.21%1 Year Performance204.95%39.61%36.57%27.31% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.1591 of 5 stars$4.70+32.0%N/A+99.4%$17.16M$11.39M-1.7820News CoverageGap UpTrading HaltedHigh Trading VolumeACXPAcurx Pharmaceuticals2.4865 of 5 stars$1.85+0.5%N/A-48.0%$30.06MN/A-1.593Earnings ReportAnalyst ForecastShort Interest ↓News CoveragePositive NewsALTSJanoneN/A$2.32-1.3%N/AN/A$30.01M$2.17M0.00170Short Interest ↓News CoverageEYENEyenovia3.5732 of 5 stars$0.51+8.6%N/A-65.8%$29.74MN/A-0.6340Earnings ReportAnalyst ForecastShort Interest ↓News CoverageINKTMiNK Therapeutics3.0012 of 5 stars$0.78+4.0%N/A-12.7%$29.66MN/A-1.5930Short Interest ↓News CoveragePMNProMIS Neurosciences1.2175 of 5 stars$0.98-1.0%N/A-34.7%$29.29M$10,000.00-1.636Short Interest ↑News CoverageGap DownPLURPluri0.1983 of 5 stars$5.53+8.4%N/A+17.6%$27.90M$330,000.00-0.94150Short Interest ↑Gap DownHigh Trading VolumeRNXTRenovoRx2.5626 of 5 stars$1.10-5.2%N/A+3.8%$27.83MN/A-1.836Short Interest ↓News CoveragePositive NewsGap DownTPSTTempest Therapeutics3.0943 of 5 stars$1.08-1.8%N/A-72.0%$27.73MN/A-0.6720Analyst ForecastShort Interest ↓News CoverageICCCImmuCell0.7407 of 5 stars$3.65+3.4%N/A-34.8%$27.65M$17.47M-6.8975Short Interest ↓News CoverageESLAEstrella Immunopharma1.571 of 5 stars$0.80+5.3%N/A-33.9%$27.56MN/A-0.41N/AUpcoming EarningsShort Interest ↓Positive NewsGap Down Related Companies and Tools Related Companies Acurx Pharmaceuticals Alternatives Janone Alternatives Eyenovia Alternatives MiNK Therapeutics Alternatives ProMIS Neurosciences Alternatives Pluri Alternatives RenovoRx Alternatives Tempest Therapeutics Alternatives ImmuCell Alternatives Estrella Immunopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PULM) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
